Urothelial Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Urothelial Cancer Drugs Market is segmented By Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma), By Treatment (Chemotherapy, Immunotherapy), By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Cancer Institutes, Ambulatory Surgical Centers), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Urothelial Cancer Drugs Market Overview

(200pages) A Report by DataM Intelligence estimates the Global Urothelial Cancer Drugs market to grow at a high CAGR Of 21.2% during the forecast period 2023- 2030. The North American region has been dominating the urothelial cancer drugs market, due to factors, such as the presence of a large target population, increased adoption of novel therapeutics. The competitive rivalry intensifies with Genentech, Bristol-Myers Squibb., Merck & Co., Inc., and others operating in the market.

Urothelial cancer is a multifocal malignancy associated with the reno-urinary system. Renal parenchyma often develops a high-grade scirrhous mass formation and turns into a malignant tumor. It can spread to the areas around the bladder or other parts of the body (metastasis). This is called advanced urothelial carcinoma.

Urothelial Cancer Drugs Market Scope

To know more insights  Download Sample

Urothelial Cancer Drugs Industry Dynamics

The global urothelial cancer drug market growth is driven by the rising geriatric population across the world and frequent doses of therapy requirements in the treatment of urothelial carcinoma. 

Frequent doses of therapy  in the treatment of urothelial cancer lead to the growth of the market 

The high recurrence rate of patients suffering from urothelial cancer is stimulating the growth of the urothelial cancer drugs market. The new novel drugs developed by pharmaceutical companies are likely to anticipate substantial growth in the urothelial cancer drugs market.  For instance, in April 2020, China National Medical Products Administration (NMPA) approved tislelizumab developed by BeiGene to treat advanced/metastatic urothelial carcinoma. Several novel treatments are predicted to see approvals, further supporting the growth of the market.

High costs in the research and development of novel drugs will hinder the market growth

High costs in the research and development of novel drugs and the emergence of generic drugs in the market are likely to hinder the growth of the urothelial cancer drugs market. Apart from this, the rising cost of branded drugs may also impact the growth of the urothelial cancer drugs market.

Urothelial Cancer Drugs Industry Analysis

The global urothelial cancer drugs market provides in-depth analysis of the market based on various industry factors such as porter's five forces analysis, supply chain analysis, pricing analysis, regulatory analysis, reimbursement analysis, unmet needs, etc.

COVID-19 Impact On Urothelial Cancer Drugs Market

COVID-19 pandemic forced cancer patients to weigh the potential benefit of a face-to-face visit and treatment with the risks of catching the virus. The pandemic has impacted every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research. This factor will hinder the growth of the market.

Urothelial Cancer Drugs Market Segmentation Analysis

The urothelial carcinoma segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

Urothelial carcinoma (UC)is the most common cancer and requires a high cost of the frequent chemotherapy required, urothelial carcinoma occurs in the urothelial carcinoma of the bladder (UCB) with the upper tract. Urothelial carcinoma is caused in the bladder and comprises almost 90.0% of the total bladder cancers. The major problem with urothelial carcinoma is that it starts from any part of the urinary tract, pelvis, bladder, and urethra. It is the most common type of bladder, ureter, urethra, and urachus cancer.

Urothelial cell carcinoma is also known as transitional cell carcinoma. Bladder transitional cell carcinoma (TCC) is the most common tumor of the entire urinary system and TCC is the most common primary neoplasm of the urinary bladder. Cancer of the ureter may not have symptoms in the early stages of the disease. However, symptoms may appear as the cancer grows. These include persistent back pain, blood in the urine, painful or frequent urination, fatigue unexplained weight loss. These symptoms are associated with cancer of the ureter and other health conditions.

Urothelial Cancer Drugs Market Geographical Growth

North America region holds the largest market share of the global urothelial cancer drugs market 

The North American region has been dominating the urothelial cancer drugs market, due to factors, such as the presence of a large target population, increased adoption of novel therapeutics, and multiple product launches, along with a rising need to tackle bladder cancer. 

The American Cancer Society’s estimates for bladder cancer in the United States for 2020 are about 81,400 new cases of bladder cancer and about 17,980 deaths from bladder cancer. A large number of bladder cancer cases increased awareness in the society, and healthcare facilities with good distribution channels are some of the important factors, which makes the market in the region grow well over the forecast period.

Urothelial Cancer Drugs Company and Competitive Landscape

The global urothelial cancer drugs market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Novartis AG, GlaxoSmithKline, Genentech, Bristol-Myers Squibb, Sanofi S.A., Eisai Co., Ltd., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., UroGen Pharma Ltd., Immunomedics, Inc., and others. 
Immunomedics, Inc.

Overview:

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

Product Portfolio: The Company’s portfolio is comprised of monoclonal antibody (MAb) medicines to treat cancer, autoimmune conditions, and other diseases. Its lead product, epratuzumab, is in development for the treatment of lupus; biopharmaceutical firm UCB has licensed the drug for further applications in autoimmune diseases but is exiting that partnership. Immunomedics is also conducting clinical trials for epratuzumab as an oncology treatment for non-Hodgkin's lymphoma. Other drugs in clinical trials aim to treat various cancers, including pancreatic cancer and multiple myeloma. It also makes diagnostic imaging products; its majority-owned IBC Pharmaceuticals develops radio therapeutics for applications in oncology treatments. 

The global urothelial cancer drugs market report would provide access to approximately 61 market data tables, 54 figures, and in the range of 200 (approximate) pages.